Zobrazeno 1 - 10
of 153
pro vyhledávání: '"David M, Thomas"'
Autor:
Subotheni Thavaneswaran, Frank Lin, John P. Grady, David Espinoza, Min Li Huang, Sarah Chinchen, Lucille Sebastian, Maya Kansara, Tony Mersiades, Chee Khoon Lee, Jayesh Desai, Peter Grimison, Michael Brown, Michael Millward, Rosemary Harrup, Ken O’Byrne, Adnan Nagrial, Paul Craft, John Simes, Anthony M. Joshua, David M. Thomas
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-10 (2024)
Abstract This single-arm phase II non-randomised trial (ACTRN12619001265167) evaluated trastuzumab emtansine in solid cancers with HER2 amplification or mutation detected by comprehensive genomic profiling. The primary objective was objective respons
Externí odkaz:
https://doaj.org/article/56a6cbd28f68431a92cbd65b7b352b9c
Autor:
Doah Cho, Sarah J. Lord, Robyn Ward, Maarten IJzerman, Andrew Mitchell, David M. Thomas, Saskia Cheyne, Andrew Martin, Rachael L. Morton, John Simes, Chee Khoon Lee
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Advances in targeted therapy development and tumor sequencing technology are reclassifying cancers into smaller biomarker-defined diseases. Randomized controlled trials (RCTs) are often impractical in rare diseases, leading to calls for s
Externí odkaz:
https://doaj.org/article/01054442bb48485e8ed565d3f77224e0
Autor:
Fei Deng, Yi Li, Biyao Yang, Rui Sang, Wei Deng, Maya Kansara, Frank Lin, Subotheni Thavaneswaran, David M. Thomas, Ewa M. Goldys
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract Control of CRISPR/Cas12a trans-cleavage is crucial for biosensor development. Here, we show that small circular DNA nanostructures which partially match guide RNA sequences only minimally activate Cas12a ribonucleoproteins. However, lineariz
Externí odkaz:
https://doaj.org/article/b1ba2e8000dc4de2a474801d83099626
Autor:
Imogen R. Walpole, Farzana Y Zaman, Peinan Zhao, Vikki M. Marshall, Frank P. Lin, David M. Thomas, Mark Shackleton, Albert A. Antolin, Malaka Ameratunga
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 4, Pp n/a-n/a (2024)
Abstract Purpose Systematic repurposing of approved medicines for another indication may accelerate drug development in oncology. We present a strategy combining biomarker testing with drug repurposing to identify new treatments for patients with adv
Externí odkaz:
https://doaj.org/article/b76bd679fe7643cd84c5891446f65a08
Autor:
Radwa Sharaf, Dexter X. Jin, John Grady, Christine Napier, Ericka Ebot, Garrett M. Frampton, Lee A. Albacker, David M. Thomas, Meagan Montesion
Publikováno v:
npj Genomic Medicine, Vol 8, Iss 1, Pp 1-10 (2023)
Abstract Tumor cells need to activate a telomere maintenance mechanism, enabling limitless replication. The bulk of evidence supports that sarcomas predominantly use alternative lengthening of telomeres (ALT) mechanism, commonly associated with alter
Externí odkaz:
https://doaj.org/article/392b82449b0c49749d70a0f47dafbda6
Autor:
Maya Kansara, Neeru Bhardwaj, Subotheni Thavaneswaran, Chang Xu, Jessica K. Lee, Lo‐Bin Chang, Russell W. Madison, Frank Lin, Eugene Hsu, Vipul Kumar Patel, Alexey Aleshin, Geoffrey R. Oxnard, John Simes, Halla Nimeiri, David M. Thomas
Publikováno v:
Molecular Oncology, Vol 17, Iss 2, Pp 298-311 (2023)
There is an urgent need to identify biomarkers of early response that can accurately predict the benefit of immune checkpoint inhibitors (ICI). Patients receiving durvalumab/tremelimumab had tumor samples sequenced before treatment (baseline) to iden
Externí odkaz:
https://doaj.org/article/c442c4094d7d4fbb9a169db3f368978a
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-8 (2023)
Abstract Science has made remarkable advances in understanding the molecular basis of disease, generating new and effective rationally-designed treatments at an accelerating rate. Ironically, the successes of science is creating a crisis in the affor
Externí odkaz:
https://doaj.org/article/2dda817edd4844f79e3b66e826ef0095
Autor:
Mrinal M. Gounder, Narasimhan P. Agaram, Sally E. Trabucco, Victoria Robinson, Richard A. Ferraro, Sherri Z. Millis, Anita Krishnan, Jessica Lee, Steven Attia, Wassim Abida, Alexander Drilon, Ping Chi, Sandra P. D’ Angelo, Mark A. Dickson, Mary Lou Keohan, Ciara M. Kelly, Mark Agulnik, Sant P. Chawla, Edwin Choy, Rashmi Chugh, Christian F. Meyer, Parvathi A. Myer, Jessica L. Moore, Ross A. Okimoto, Raphael E. Pollock, Vinod Ravi, Arun S. Singh, Neeta Somaiah, Andrew J. Wagner, John H. Healey, Garrett M. Frampton, Jeffrey M. Venstrom, Jeffrey S. Ross, Marc Ladanyi, Samuel Singer, Murray F. Brennan, Gary K. Schwartz, Alexander J. Lazar, David M. Thomas, Robert G. Maki, William D. Tap, Siraj M. Ali, Dexter X. Jin
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
Comprehensive molecular profiles are required to understand and treat sarcomas, which comprise more than 70 different subtypes. Here, the authors profile the genomic landscape of 7494 sarcomas across 44 histologies using targeted panel sequencing and
Externí odkaz:
https://doaj.org/article/ded28dd2538e4114ba7de3e78b153f38
Autor:
Frank P. Lin, Subotheni Thavaneswaran, John P. Grady, Mandy Ballinger, Maya Kansara, Samantha R. Oakes, Jayesh Desai, Chee Khoon Lee, John Simes, David M. Thomas
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-10 (2021)
Abstract While several resources exist that interpret therapeutic significance of genomic alterations in cancer, many regional real-world issues limit access to drugs. There is a need for a pragmatic, evidence-based, context-adapted tool to guide cli
Externí odkaz:
https://doaj.org/article/6a749ceadf654e848f7ee68f6d873817
Autor:
Andre E. Minoche, Ben Lundie, Greg B. Peters, Thomas Ohnesorg, Mark Pinese, David M. Thomas, Andreas Zankl, Tony Roscioli, Nicole Schonrock, Sarah Kummerfeld, Leslie Burnett, Marcel E. Dinger, Mark J. Cowley
Publikováno v:
Genome Medicine, Vol 13, Iss 1, Pp 1-19 (2021)
Abstract Whole genome sequencing (WGS) has the potential to outperform clinical microarrays for the detection of structural variants (SV) including copy number variants (CNVs), but has been challenged by high false positive rates. Here we present Cli
Externí odkaz:
https://doaj.org/article/5ca2cd5ac8244f85b8154567b73ff3e2